Banner Life Sciences LLC
🇺🇸United States
Observational Study of Persistence on Bafiertam Treatment In Routine Clinical Practice
- Conditions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Banner Life Sciences LLC
- Target Recruit Count
- 100
- Registration Number
- NCT05978531
- Locations
- 🇵🇷
Caribbean Center for Clinical Research, Guaynabo, Puerto Rico
🇺🇸Regina Berkovich, MD, PhD Inc., West Hollywood, California, United States
🇺🇸Arizona Neuroscience Research, LLC, Phoenix, Arizona, United States
Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2022-01-06
- Lead Sponsor
- Banner Life Sciences LLC
- Target Recruit Count
- 46
- Registration Number
- NCT05181215
- Locations
- 🇺🇸
BioPharma Services, Inc., Saint Louis, Missouri, United States
Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® From Dimethyl Fumarate
Withdrawn
- Conditions
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- Banner Life Sciences LLC
- Registration Number
- NCT04925778
Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-09-30
- Last Posted Date
- 2022-12-30
- Lead Sponsor
- Banner Life Sciences LLC
- Target Recruit Count
- 50
- Registration Number
- NCT04570670
Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Banner Life Sciences LLC
- Target Recruit Count
- 210
- Registration Number
- NCT04022473
- Locations
- 🇺🇸
BioPharma Services, Inc., Columbia, Missouri, United States
© Copyright 2024. All Rights Reserved by MedPath